LifeSplice was awarded an NIH Phase I/Phase II SBIR Fast-Track CREATE grant. The $670K Phase I grant foc...
LifeSplice was awarded an NIH Phase I/Phase II SBIR Fast-Track CREATE grant. The $670K Phase I grant foc...
LifeSplice was awarded an NIH R21 grant for the initial development of SMOs to alter the expression of RA...
LifeSplice Pharma is pleased to announce the publication of the article "AMPA GluA1-flip targeted oligonucleotide therapy reduces...